Beyond insulin resistance in NASH: TNF-alpha or adiponectin? - PubMed (original) (raw)
Beyond insulin resistance in NASH: TNF-alpha or adiponectin?
Jason M Hui et al. Hepatology. 2004 Jul.
Abstract
Adiponectin has antilipogenic and anti-inflammatory effects, while tumor necrosis factor alpha (TNF-alpha) reduces insulin sensitivity and has proinflammatory effects. We examined (1) the extent to which hypoadiponectinemia and TNF-alpha activation are features of nonalcoholic steatohepatitis (NASH) and (2) whether serum levels of these markers correlate with the severity of histological changes in 109 subjects with nonalcoholic fatty liver disease (NAFLD), including 80 with NASH and 29 with simple steatosis. By multivariate analysis, subjects with NASH had reduced adiponectin level and increased TNF-alpha and soluble TNF receptor 2 (sTNFR2)-but not leptin levels, compared with controls matched by age, sex, and body mass index; these differences were independent of the increased insulin resistance (by homeostasis model [HOMA-IR]) in NASH. When compared with simple steatosis, NASH was associated with lower adiponectin levels and higher HOMA-IR, but there were no significant differences in the levels of TNF-alpha and sTNFR2. The majority of subjects with steatohepatitis (77%) had adiponectin levels less than 10 microg/mL and HOMA-IR greater than 3 units, but only 33% of those with pure steatosis had these findings. HOMA-IR and low serum adiponectin were also independently associated with increased grades of hepatic necroinflammation. In conclusion, hypoadiponectinemia is a feature of NASH independent of insulin resistance. Reduced adiponectin level is associated with more extensive necroinflammation and may contribute to the development of necroinflammatory forms of NAFLD.
Comment in
- Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine.
Czaja MJ. Czaja MJ. Hepatology. 2004 Jul;40(1):19-22. doi: 10.1002/hep.20328. Hepatology. 2004. PMID: 15239081 Review. No abstract available. - Reduced plasma adiponectin in NASH: central obesity as an underestimated causative risk factor.
Tietge UJ, Schmidt HH, Schütz T, Dippe P, Lochs H, Pirlich M. Tietge UJ, et al. Hepatology. 2005 Feb;41(2):401; author reply 401-2. doi: 10.1002/hep.20546. Hepatology. 2005. PMID: 15660429 No abstract available.
Similar articles
- Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, Serfaty L. Lemoine M, et al. Liver Int. 2009 Oct;29(9):1431-8. doi: 10.1111/j.1478-3231.2009.02022.x. Epub 2009 Apr 24. Liver Int. 2009. PMID: 19422483 - Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients.
Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Durante-Mangoni E, et al. Aliment Pharmacol Ther. 2006 Nov 1;24(9):1349-57. doi: 10.1111/j.1365-2036.2006.03114.x. Aliment Pharmacol Ther. 2006. PMID: 17059516 - Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K, Szczesniak P, Kumor A, Jasinska A, Omulecka A, Pietruczuk M, Orszulak-Michalak D, Sporny S, Malecka-Panas E. Krawczyk K, et al. J Physiol Pharmacol. 2009 Oct;60 Suppl 3:71-5. J Physiol Pharmacol. 2009. PMID: 19996485 - The role of cytokines in non-alcoholic fatty liver disease.
Tilg H. Tilg H. Dig Dis. 2010;28(1):179-85. doi: 10.1159/000282083. Epub 2010 May 7. Dig Dis. 2010. PMID: 20460908 Review. - [Clinical features of NASH].
Shimada M, Takase S. Shimada M, et al. Nihon Rinsho. 2006 Jun;64(6):1114-8. Nihon Rinsho. 2006. PMID: 16768118 Review. Japanese.
Cited by
- B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease.
Miyake T, Abe M, Tokumoto Y, Hirooka M, Furukawa S, Kumagi T, Hamada M, Kawasaki K, Tada F, Ueda T, Hiasa Y, Matsuura B, Onji M. Miyake T, et al. Hepatol Int. 2013 Jun;7(2):539-47. doi: 10.1007/s12072-012-9345-8. Epub 2012 Feb 9. Hepatol Int. 2013. PMID: 26201785 - Visceral adipose tissue area as an independent risk factor for elevated liver enzyme in nonalcoholic fatty liver disease.
Chung GE, Kim D, Kwark MS, Kim W, Yim JY, Kim YJ, Yoon JH. Chung GE, et al. Medicine (Baltimore). 2015 Mar;94(9):e573. doi: 10.1097/MD.0000000000000573. Medicine (Baltimore). 2015. PMID: 25738475 Free PMC article. - Upregulation of UCP2 by adiponectin: the involvement of mitochondrial superoxide and hnRNP K.
Zhou M, Xu A, Tam PK, Lam KS, Huang B, Liang Y, Lee IK, Wu D, Wang Y. Zhou M, et al. PLoS One. 2012;7(2):e32349. doi: 10.1371/journal.pone.0032349. Epub 2012 Feb 16. PLoS One. 2012. PMID: 22359684 Free PMC article. - Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.
Jichitu A, Bungau S, Stanescu AMA, Vesa CM, Toma MM, Bustea C, Iurciuc S, Rus M, Bacalbasa N, Diaconu CC. Jichitu A, et al. Diagnostics (Basel). 2021 Apr 12;11(4):689. doi: 10.3390/diagnostics11040689. Diagnostics (Basel). 2021. PMID: 33921359 Free PMC article. Review. - Vitamin D: a new player in non-alcoholic fatty liver disease?
Eliades M, Spyrou E. Eliades M, et al. World J Gastroenterol. 2015 Feb 14;21(6):1718-27. doi: 10.3748/wjg.v21.i6.1718. World J Gastroenterol. 2015. PMID: 25684936 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources